Bullous Pemphigoid Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Bullous Pemphigoid Epidemiology Forecast Report Coverage

Expert Market Research's “Bullous Pemphigoid Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Bullous Pemphigoid. It projects the future incidence and prevalence rates of Bullous Pemphigoid cases across various populations.  The study covers age, gender, and type as major determinants of the Bullous Pemphigoid population. The report highlights patterns in the prevalence of Bullous Pemphigoid over time and projects future trends based on multiple variables.

Bullous Pemphigoid Understanding: Disease Overview

Bullous pemphigoid refers to a rare autoimmune skin disease that usually starts with an itchy, raised rash, reflecting a characteristic autoimmune skin disorder pattern. In this condition, the immune system of the body starts attacking healthy skin tissue, leading to large fluid-filled blisters and sometimes open sores, consistent with a progressive dermatological blistering disease pattern. The average age of onset of this disease is estimated to be 65 years, indicating a strong age-related disease distribution. Bullous pemphigoid is reported to occur throughout the world, with no apparent racial predilection.

Bullous Pemphigoid Epidemiology Perspective

The Bullous Pemphigoid epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Bullous Pemphigoid epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Bullous Pemphigoid and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• As per Orphanet, the incidence of bullous pemphigoid is increasing, with rates reported between 2 to 22 cases per 1,000,000 worldwide, reflecting a rising rare autoimmune disease incidence profile.
• A 2022 meta-analysis in the British Journal of Dermatology reported a cumulative incidence of 8.2 per million people and an incidence rate of 34.2 per million person-years, indicating evolving population-level dermatology trend dynamics.
• Research studies indicate that bullous pemphigoid shows a slight female predominance, with a reported female-to-male ratio of approximately 1.2:1, highlighting gender-based variation in disease occurrence.
• According to a study published in Frontiers of Medicine (2018), the annual incidence ranges from 2.4 to 23 cases per million in the general population, increasing to 190 to 312 cases per million in individuals above 80 years, reflecting a strong age-stratified disease occurrence gradient.

Read more about this report - Request a Free Sample

Country-wise Bullous Pemphigoid Epidemiology

The bullous pemphigoid epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of bullous pemphigoid varies significantly between countries owing to differences in genetic predispositions, environmental triggers (including infections and allergens), the size of the aging population, and variations in healthcare access and diagnostic capabilities, reflecting a distinct regional autoimmune susceptibility pattern. In the United States, the prevalence of bullous pemphigoid has been reported at approximately 6–13 cases per 100,000 population, while in the United Kingdom, prevalence reaches up to 47.99 cases per 100,000 population, indicating a relatively higher disease burden.

Bullous Pemphigoid: Treatment Overview

Steroid tablets, such as prednisone or prednisolone, are considered the primary treatment for bullous pemphigoid, reflecting standard clinical management patterns. Doxycycline, azathioprine, mycophenolate, dapsone, methotrexate, or intravenous immunoglobulin are often added to reduce steroid dose and minimize associated side effects, supporting evolving bullous pemphigoid disease progression patterns. Long-term remission is usually observed in most patients after 2 to 3 years of treatment; however, some patients require prolonged therapy for several years due to persistent or relapsing disease activity.

Key Questions Answered

• What are the key findings of bullous pemphigoid epidemiology in the 8 major markets?
• What will be the total number of patients with Bullous Pemphigoid across the 8 major markets during the forecast period?
• What was the country-wise bullous pemphigoid epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of bullous pemphigoid patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of Bullous Pemphigoid during the forecast period of 2026-2035?
• What are the currently available treatments for bullous pemphigoid?
• What are the disease risks, signs, symptoms, and unmet needs of bullous pemphigoid?

Scope of the Bullous Pemphigoid Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Bullous Pemphigoid based on several factors.
• Bullous Pemphigoid Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The Bullous Pemphigoid report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Bullous Pemphigoid Market

Bullous Pemphigoid Treatment Market